Live Breaking News & Updates on Gilmore Neil Oneill|Page 5

Stay updated with breaking news from Gilmore neil oneill. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

FY2023 EPS Estimates for Editas Medicine, Inc. (NASDAQ:EDIT) Lifted by Cantor Fitzgerald

Editas Medicine, Inc. (NASDAQ:EDIT – Free Report) – Analysts at Cantor Fitzgerald upped their FY2023 earnings estimates for Editas Medicine in a report issued on Tuesday, August 8th. Cantor Fitzgerald analyst R. Bienkowski now forecasts that the company will post earnings per share of ($2.35) for the year, up from their prior estimate of ($2.43). […] ....

Gilmore Neil Oneill , Baisong Mei , Cantor Fitzgerald , Raymond James , Headlands Technologies , Allspring Global Investments Holdings , Editas Medicine Inc , Securities Exchange Commission , Covestor Ltd , Editas Medicine , Free Report , Get Free Report , Global Investments Holdings , Neilo Neill , Exchange Commission , Leber Congenital Amaurosis , Editas Medicine Daily , Nasdaq Edit , Earnings Estimates ,

Editas Medicine (NASDAQ:EDIT) Stock Rating Reaffirmed by Oppenheimer

Oppenheimer restated their market perform rating on shares of Editas Medicine (NASDAQ:EDIT – Free Report) in a research report report published on Thursday morning, Benzinga reports. They currently have a $12.00 price target on the stock. EDIT has been the subject of a number of other research reports. StockNews.com lowered Editas Medicine from a hold […] ....

Baisong Mei , Gilmore Neil Oneill , Raymond James , Congress Asset Management Co , Dimensional Fund Advisors , Silicon Hills Wealth Management , Editas Medicine Company Profile , Securities Exchange Commission , Editas Medicine Inc , Editas Medicine , Free Report , Medicine Trading Down , Get Free Report , Neilo Neill , Exchange Commission , Hills Wealth Management , Asset Management , Fund Advisors , Leber Congenital Amaurosis , Editas Medicine Daily , Nasdaq Edit , Reiterated Rating , Oppenheimer Holdings Inc ,

Chardan Capital Lowers Editas Medicine (NASDAQ:EDIT) Price Target to $19.00

Editas Medicine (NASDAQ:EDIT – Free Report) had its price objective cut by Chardan Capital from $22.00 to $19.00 in a report published on Wednesday morning, MarketBeat Ratings reports. They currently have a buy rating on the stock. EDIT has been the topic of a number of other reports. Raymond James upgraded shares of Editas Medicine […] ....

Gilmore Neil Oneill , Baisong Mei , Raymond James , Dimensional Fund Advisors , Securities Exchange Commission , Editas Medicine Inc , Renaissance Technologies , Blackrock Inc , Editas Medicine , Free Report , Chardan Capital , Marketbeat Ratings , Medicine Trading Down , Get Free Report , Exchange Commission , Neilo Neill , Street Corp , Fund Advisors , Asset Management , Leber Congenital Amaurosis , Editas Medicine Daily , Nasdaq Edit , Lower Price Target ,

Editas Medicine (NASDAQ:EDIT) Releases Quarterly Earnings Results, Beats Estimates By $0.20 EPS

Editas Medicine (NASDAQ:EDIT – Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.76) by $0.20, Briefing.com reports. The business had revenue of $2.89 million during the quarter, compared to analysts’ expectations of $4.17 million. Editas Medicine had […] ....

Baisong Mei , Gilmore Neil Oneill , Raymond James , Covestor Ltd , Great West Life Assurance Co , Sigma Securities , Editas Medicine Inc , Koss Olinger Consulting , Securities Exchange Commission , Editas Medicine , Get Free Report , Exchange Commission , Neilo Neill , West Life Assurance , Olinger Consulting , Two Sigma Securities , Chardan Capital , Leber Congenital Amaurosis , Editas Medicine Daily , Nasdaq Edit ,

Editas Medicine (NASDAQ:EDIT) Announces Quarterly Earnings Results, Beats Estimates By $0.20 EPS

Editas Medicine (NASDAQ:EDIT – Get Free Report) announced its earnings results on Wednesday. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.76) by $0.20, Briefing.com reports. The firm had revenue of $2.89 million for the quarter, compared to the consensus estimate of $4.17 million. Editas Medicine had a negative net […] ....

Raymond James , Gilmore Neil Oneill , Baisong Mei , Koss Olinger Consulting , Penserra Capital Management , Covestor Ltd , Great West Life Assurance Co , Editas Medicine Inc , Editas Medicine , Get Free Report , Chardan Capital , Neilo Neill , Capital Management , West Life Assurance , Leber Congenital Amaurosis , Editas Medicine Daily , Nasdaq Edit ,